Bio-Thera Solutions Reports the Initiation of Combined P-I/P-III Study of BAT3306 (Biosimilar, Keytruda)
Shots:
- Bio-Thera Solutions has commenced the patients dosing under the combined P-I/P-III study evaluating BAT3306, a biosimilar version of Keytruda (pembrolizumab)
- The trial aims at assessing PK profile, safety & efficacy of BAT3306 vs Keytruda among patients (n=676) with non-squamous non-small cell lung cancer (nsNSCLC)
- In addition, the company is also developing biosimilars of golimumab, secukinumab & mepolizumab plus includes BAT1806 (biosimilar of tocilizumab), approved by the US FDA, EMA & NMPA, BAT1706 (biosimilar of bevacizumab), approved by the US FDA & NMPA as well as BAT2206 (biosimilar of ustekinumab), filed with the US FDA, EMA & NMPA
Ref: Bio-Thera | Image: Bio-Thera
Related News:- Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
